Back to Search Start Over

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Authors :
Rini BI
Battle D
Figlin RA
George DJ
Hammers H
Hutson T
Jonasch E
Joseph RW
McDermott DF
Motzer RJ
Pal SK
Pantuck AJ
Quinn DI
Seery V
Voss MH
Wood CG
Wood LS
Atkins MB
Source :
Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Dec 20; Vol. 7 (1), pp. 354. Date of Electronic Publication: 2019 Dec 20.
Publication Year :
2019

Abstract

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

Details

Language :
English
ISSN :
2051-1426
Volume :
7
Issue :
1
Database :
MEDLINE
Journal :
Journal for immunotherapy of cancer
Publication Type :
Academic Journal
Accession number :
31856918
Full Text :
https://doi.org/10.1186/s40425-019-0813-8